[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 28 of about 28
1. Tadokoro M, Masuda H, Fujii Y, Kobayashi T, Kageyama Y, Kihara K: Late relapse of stage I testicular seminoma metastatic to just a para-ureteropelvic region. Int J Urol; 2004 Nov;11(11):1044-6
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Computed tomography scans of the abdomen showed a bulky tumor around the ureteropelvic region without para-aortic lymph node enlargement, but did not show a clear distinction between a recurrence of the testicular tumor and an invasive ureteral tumor.
  • After the patient underwent two cycles of chemotherapy with cisplatin and etoposide, the tumor mass decreased by approximately 60% and beta-hCG levels returned to normal.
  • We then performed a resection of the residual tumor involving the upper ureter and left kidney and a retroperitoneal lymph node dissection under a clinical diagnosis of recurrence of the testicular tumor.
  • [MeSH-major] Kidney Pelvis / pathology. Neoplasm Recurrence, Local / pathology. Seminoma / pathology. Testicular Neoplasms / pathology. Ureteral Neoplasms / secondary
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chorionic Gonadotropin, beta Subunit, Human / blood. Cisplatin / administration & dosage. Etoposide / administration & dosage. Humans. Hydronephrosis / etiology. Male

  • Genetic Alliance. consumer health - Seminoma.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15509217.001).
  • [ISSN] 0919-8172
  • [Journal-full-title] International journal of urology : official journal of the Japanese Urological Association
  • [ISO-abbreviation] Int. J. Urol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Chorionic Gonadotropin, beta Subunit, Human; 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


2. Giannarini G, Schumacher MC, Thalmann GN, Bitton A, Fleischmann A, Studer UE: Elective management of transitional cell carcinoma of the distal ureter: can kidney-sparing surgery be advised? BJU Int; 2007 Aug;100(2):264-8
Genetic Alliance. consumer health - Transitional cell carcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Elective management of transitional cell carcinoma of the distal ureter: can kidney-sparing surgery be advised?
  • OBJECTIVE: To determine the long-term oncological outcome of patients with primary transitional cell carcinoma (TCC) of the distal ureter electively treated with either kidney-sparing surgery (KSS) or radical nephroureterectomy (RNU) in a retrospective, non-randomized, single-centre study.
  • PATIENTS AND METHODS: Of 43 consecutive patients with a primary solitary distal ureter TCC, 19 had KSS, consisting of distal ureter resection with bladder cuff excision and ureter reimplantation, and 24 had RNU with bladder cuff excision.
  • Five of the 19 patients treated by KSS and six of the 24 treated by RNU died from metastatic disease despite chemotherapy.
  • CONCLUSION: Treatment by distal ureteric resection is feasible in patients with primary TCC of the distal ureter.
  • Furthermore, kidney preservation is advantageous if adjuvant or salvage chemotherapy is required.
  • [MeSH-major] Carcinoma, Transitional Cell / surgery. Kidney / surgery. Nephrectomy / methods. Ureter / surgery. Ureteral Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease-Free Survival. Feasibility Studies. Follow-Up Studies. Humans. Hydronephrosis / complications. Hydronephrosis / pathology. Hydronephrosis / surgery. Middle Aged. Neoplasm Recurrence, Local. Retrospective Studies. Treatment Outcome. Urinary Bladder Neoplasms / complications. Urinary Bladder Neoplasms / pathology. Urinary Bladder Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17532855.001).
  • [ISSN] 1464-4096
  • [Journal-full-title] BJU international
  • [ISO-abbreviation] BJU Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


3. Takagi S, Gohji K, Iwamoto Y, Masuda H, Segawa N, Kiura H, Ueda H, Katsuoka Y: [Ureter cancer of complete double renal pelvis and ureter: a case report]. Hinyokika Kiyo; 2002 Dec;48(12):761-4
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Ureter cancer of complete double renal pelvis and ureter: a case report].
  • Intravenous pyelography, computerized tomography and magnetic resonance imaging revealed ureteral tumors of the complete left double renal pelvis and the ureter.
  • An endoscopic examination disclosed a papillary tumor from the left ureteral orifice of the lower pole of the kidney.
  • A transurethral resection of the tumor was done, and the pathological features revealed transitional cell carcinoma (PTa, grade 2).
  • A left nephroureterectomy and a partial cystectomy were also carried out; macroscopic examinations showed a non-papillary tumor on the middle portion of the left ureter originating from the upper pole of the kidney.
  • Adjuvant chemotherapy (M-VAC) was administered but discontinued because of severe side effects.
  • Dispite recurrence with retro-peritoneal lymph node metastasis, the patient is alive and again undergoing M-VAC chemotherapy 22 months after the initial surgery.
  • However, the evaluation of the chemotherapy was "no change".
  • [MeSH-major] Carcinoma, Transitional Cell / surgery. Kidney Neoplasms / surgery. Kidney Pelvis / abnormalities. Neoplasms, Multiple Primary. Ureter / abnormalities. Ureteral Neoplasms / surgery
  • [MeSH-minor] Aged. Chemotherapy, Adjuvant. Humans. Lymphatic Metastasis. Male. Neoplasm Recurrence, Local. Urinary Bladder Neoplasms / pathology. Urinary Bladder Neoplasms / surgery. Urologic Surgical Procedures

  • Genetic Alliance. consumer health - Kidney cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12613013.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 16
  •  go-up   go-down


Advertisement
4. Onishi T, Franco OE, Shibahara T, Arima K, Sugimura Y: Papillary adenocarcinoma of the renal pelvis and ureter producing carcinoembryonic antigen, carbohydrate antigen 19-9 and carbohydrate antigen 125. Int J Urol; 2005 Feb;12(2):214-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Papillary adenocarcinoma of the renal pelvis and ureter producing carcinoembryonic antigen, carbohydrate antigen 19-9 and carbohydrate antigen 125.
  • We report a case of advanced renal pelvis and ureter adenocarcinoma producing carcinoembryonic antigen (CEA), carbohydrate antigen 19-9 (CA19-9) and carbohydrate antigen 125 (CA125).
  • A 72-year-old woman was diagnosed with right renal pelvic and ureter tumor with para-aortic lymph node swelling.
  • Biopsy of the ureteral mass revealed papillary adenocarcinoma.
  • The patient was successfully treated with paclitaxel/carboplatin chemotherapy followed by surgery.
  • [MeSH-major] Adenocarcinoma, Papillary / immunology. Antigens, Neoplasm / metabolism. Kidney Neoplasms / immunology. Ureteral Neoplasms / immunology
  • [MeSH-minor] Aged. Female. Humans. Kidney Pelvis / pathology

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15733120.001).
  • [ISSN] 0919-8172
  • [Journal-full-title] International journal of urology : official journal of the Japanese Urological Association
  • [ISO-abbreviation] Int. J. Urol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antigens, Neoplasm
  •  go-up   go-down


5. Inoue K, Kamada M, Slaton JW, Fukata S, Yoshikawa C, Tamboli P, Dinney CP, Shuin T: The prognostic value of angiogenesis and metastasis-related genes for progression of transitional cell carcinoma of the renal pelvis and ureter. Clin Cancer Res; 2002 Jun;8(6):1863-70
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The prognostic value of angiogenesis and metastasis-related genes for progression of transitional cell carcinoma of the renal pelvis and ureter.
  • PURPOSE: We reported previously that angiogenesis evaluated by intratumor microvessel density (MVD), expression of such angiogenic factors as vascular endothelial cell growth factor (VEGF) and basic fibroblast growth factor (bFGF), and the matrix metalloproteinase-9:E-cadherin ratio (M:E ratio) could identify patients with advanced transitional cell carcinoma (TCC) of the bladder for whom chemotherapy and cystectomy will be unsuccessful.
  • EXPERIMENTAL DESIGN: We evaluated MVD by immunohistochemistry and the expression of angiogenic and metastasis-related factors by in situ hybridization in 55 nephroureterectomy specimens from patients who received no neoadjuvant therapy.
  • RESULTS: We found that tumor grade and pathological stage were important predictors for metastasis and survival in these patients.
  • The expression level of matrix metalloproteinase type 9 (MMP-9) and type 2 (MMP-2) and the M:E ratio correlated with MVD.
  • CONCLUSION: We suggest that the M:E ratio and E-cadherin expression may be targets for novel therapeutic strategies.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Carcinoma, Transitional Cell / blood supply. Kidney Neoplasms / blood supply. Neoplasm Proteins / metabolism. Neovascularization, Pathologic / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cadherins / genetics. Cadherins / metabolism. Disease Progression. Endothelial Growth Factors / genetics. Endothelial Growth Factors / metabolism. Female. Fibroblast Growth Factor 2 / genetics. Fibroblast Growth Factor 2 / metabolism. Humans. Intercellular Signaling Peptides and Proteins / genetics. Intercellular Signaling Peptides and Proteins / metabolism. Interleukin-8 / metabolism. Kidney Pelvis / metabolism. Lymphokines / genetics. Lymphokines / metabolism. Male. Matrix Metalloproteinase 2 / genetics. Matrix Metalloproteinase 2 / metabolism. Matrix Metalloproteinase 9 / genetics. Matrix Metalloproteinase 9 / metabolism. Middle Aged. Neoadjuvant Therapy. Neoplasm Staging. Prognosis. RNA, Messenger / metabolism. Survival Rate. Ureter / metabolism. Urinary Bladder / metabolism. Vascular Endothelial Growth Factor A. Vascular Endothelial Growth Factors

  • Genetic Alliance. consumer health - Transitional cell carcinoma.
  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12060629.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cadherins; 0 / Endothelial Growth Factors; 0 / Intercellular Signaling Peptides and Proteins; 0 / Interleukin-8; 0 / Lymphokines; 0 / Neoplasm Proteins; 0 / RNA, Messenger; 0 / Vascular Endothelial Growth Factor A; 0 / Vascular Endothelial Growth Factors; 103107-01-3 / Fibroblast Growth Factor 2; EC 3.4.24.24 / Matrix Metalloproteinase 2; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


6. Oka H, Shiraishi Y, Negoro H, Iwamura H, Moroi S, Soeda A, Takeuchi H, Kawakita M: [Clinical review of conservative management of upper urinary tract transitional cell carcinoma]. Hinyokika Kiyo; 2006 Apr;52(4):249-53
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We reviewed 18 patients with transitional cell carcinoma of the renal pelvis and ureter undergoing nephron-sparing surgery between April 1990 and Febrary 2003.
  • The tumor site was the renal pelvis in 2, ureter in 13 and ureteral orfice in 2.
  • Eight patients underwent endourological treatment and 10 patients open surgery including partial ureterectomy performed on 8 patient.
  • In the patients with tumors pT2 or higher and/or grade 3, the prognosis was poor which suggests the need for intensive therapy including lymph node dissection and/or adjuvant chemotherapy.
  • [MeSH-major] Carcinoma, Transitional Cell / surgery. Kidney Neoplasms / surgery. Kidney Pelvis. Nephrectomy / methods. Ureteral Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Survival Rate. Ureter / surgery

  • Genetic Alliance. consumer health - Transitional cell carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16686350.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


7. Favaretto RL, Shariat SF, Chade DC, Godoy G, Adamy A, Kaag M, Bochner BH, Coleman J, Dalbagni G: The effect of tumor location on prognosis in patients treated with radical nephroureterectomy at Memorial Sloan-Kettering Cancer Center. Eur Urol; 2010 Oct;58(4):574-80
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The effect of tumor location on prognosis in patients treated with radical nephroureterectomy at Memorial Sloan-Kettering Cancer Center.
  • BACKGROUND: The prognostic impact of primary tumor location on outcomes for patients with upper-tract urothelial carcinoma (UTUC) is still contentious.
  • OBJECTIVE: To test the association between tumor location and disease recurrence and cancer-specific survival (CSS) in patients treated with radical nephroureterectomy (RNU) for UTUC.
  • Patients who had previous radical cystectomy, preoperative chemotherapy, previous contralateral UTUC, or metastatic disease at presentation were excluded.
  • Tumor location was categorized as renal pelvis or ureter based on the location of the dominant tumor.
  • Tumor location was not an independent predictor for recurrence (hazard ratio: 1.19; p=0.3), and there was no difference in the probability of disease recurrence between ureteral and renal pelvic tumors (p=0.18).
  • On survival analysis, we also found no differences between ureteral and renal pelvic tumors on probability of CSS (p=0.2).
  • CONCLUSIONS: Our study did not show any differences in recurrence and CSS rates between patients with ureteral and renal pelvic tumors treated with RNU.
  • [MeSH-major] Carcinoma, Transitional Cell / surgery. Kidney Neoplasms / surgery. Kidney Pelvis. Nephrectomy. Ureter / surgery. Ureteral Neoplasms / surgery
  • [MeSH-minor] Aged. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / epidemiology. Prognosis. Retrospective Studies. Survival Rate

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 European Association of Urology. Published by Elsevier B.V. All rights reserved.
  • [Cites] J Clin Oncol. 2009 Feb 1;27(4):612-8 [19075275.001]
  • [Cites] Eur Urol. 2008 Apr;53(4):794-802 [18207313.001]
  • [Cites] J Urol. 2009 Nov;182(5):2177-81 [19758662.001]
  • [Cites] Eur Urol. 2005 Sep;48(3):438-44 [16115524.001]
  • [Cites] Am J Surg Pathol. 1998 Dec;22(12):1435-48 [9850170.001]
  • [Cites] Urology. 1998 Oct;52(4):594-601 [9763077.001]
  • [Cites] Urology. 1997 Sep;50(3):321-9 [9301692.001]
  • [Cites] Cancer. 1988 Nov 1;62(9):2016-20 [3167813.001]
  • [Cites] Cancer. 2009 Mar 15;115(6):1224-33 [19156917.001]
  • [Cites] CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49 [19474385.001]
  • [Cites] J Urol. 2009 Sep;182(3):894-9 [19616243.001]
  • [Cites] Eur Urol. 2010 Jun;57(6):1072-9 [19619934.001]
  • [Cites] J Urol. 2000 Nov;164(5):1523-5 [11025695.001]
  • [Cites] J Urol. 2004 Feb;171(2 Pt 1):621-5 [14713773.001]
  • [CommentIn] Eur Urol. 2011 Apr;59(4):e23 [21255908.001]
  • [CommentIn] Eur Urol. 2011 Jan;59(1):e2 [20980096.001]
  • [CommentIn] J Urol. 2011 Feb;185(2):463 [22088622.001]
  • (PMID = 20637540.001).
  • [ISSN] 1873-7560
  • [Journal-full-title] European urology
  • [ISO-abbreviation] Eur. Urol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / T32 CA082088
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Other-IDs] NLM/ NIHMS628548; NLM/ PMC4174409
  •  go-up   go-down


8. Czito B, Zietman A, Kaufman D, Skowronski U, Shipley W: Adjuvant radiotherapy with and without concurrent chemotherapy for locally advanced transitional cell carcinoma of the renal pelvis and ureter. J Urol; 2004 Oct;172(4 Pt 1):1271-5
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant radiotherapy with and without concurrent chemotherapy for locally advanced transitional cell carcinoma of the renal pelvis and ureter.
  • The role of adjuvant radiation therapy and chemotherapy is not well defined.
  • We retrospectively reviewed the records of 31 patients who underwent surgery followed by adjuvant radiotherapy with or without concurrent chemotherapy to determine overall outcome as well as impact of concurrent chemotherapy administration.
  • MATERIALS AND METHODS: Between 1970 and 1997, 31 patients with nonmetastatic transitional cell carcinoma of the upper urinary tract (renal pelvis in 13, ureter in 15, and renal pelvis and ureter in 3) were treated with radiotherapy following attempted curative resection.
  • The median radiation dose was 46.9 Gy.
  • Nine patients received methotrexate, cisplatin and vinblastine chemotherapy for 2 to 4 cycles, followed by concurrent cisplatin with radiation.
  • On univariate analysis patients had improved 5-year actuarial overall and disease specific survival with the administration of concurrent chemotherapy (27% vs 67%, p = 0.01 and 41% vs 76%, p = 0.06, respectively).
  • [MeSH-major] Carcinoma, Transitional Cell / drug therapy. Carcinoma, Transitional Cell / radiotherapy. Kidney Neoplasms / drug therapy. Kidney Neoplasms / radiotherapy. Kidney Pelvis. Ureteral Neoplasms / drug therapy. Ureteral Neoplasms / radiotherapy
  • [MeSH-minor] Actuarial Analysis. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Cisplatin / therapeutic use. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Metastasis / pathology. Neoplasm Recurrence, Local / pathology. Neoplasm Staging. Neoplasm, Residual / drug therapy. Neoplasm, Residual / pathology. Neoplasm, Residual / radiotherapy. Neoplasm, Residual / surgery. Outcome and Process Assessment (Health Care). Radiation-Sensitizing Agents / therapeutic use. Radiotherapy, Adjuvant. Survival Rate. Ureter / pathology. Ureter / surgery


9. Holmäng S, Thomsen J, Johansson SL: Micropapillary carcinoma of the renal pelvis and ureter. J Urol; 2006 Feb;175(2):463-6; discussion 466-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Micropapillary carcinoma of the renal pelvis and ureter.
  • MATERIALS AND METHODS: A clinical and histopathological review was performed in 943 patients with a neoplasm in the renal pelvis or ureter, diagnosed between 1971 and 1998.
  • CONCLUSIONS: The prognosis is poor since most patients with MPC of the renal pelvis and ureter initially present with advanced disease.
  • However, radiotherapy and systemic chemotherapy appear to be ineffective.
  • [MeSH-major] Carcinoma, Papillary. Kidney Neoplasms. Kidney Pelvis. Ureteral Neoplasms

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16406972.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


10. Ozsahin M, Ugurluer G, Zouhair A: Management of transitional-cell carcinoma of the renal pelvis and ureter. Swiss Med Wkly; 2009 Jun 27;139(25-26):353-6
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of transitional-cell carcinoma of the renal pelvis and ureter.
  • Transitional-cell carcinoma of the renal pelvis or ureter is a relatively rare disease.
  • The treatment of renal pelvis and ureter tumours is open or laparoscopic surgery varying from conservative to more extensive surgical procedures, i.e. radical nephroureterectomy including removal of the contents of Gerota's fascia with ipsilateral ureter and a cuff of bladder at its distal extent.
  • Most available data are from retrospective studies and surgery is the mainstay of treatment.
  • Chemotherapy and/or radiation therapy are possible adjuvant or primary treatment for selected patients; however, prospective studies are needed to confirm their use.
  • [MeSH-major] Carcinoma, Transitional Cell / surgery. Kidney Neoplasms / surgery. Ureteral Neoplasms / surgery
  • [MeSH-minor] Female. Humans. Kidney Pelvis / pathology. Kidney Pelvis / surgery. Male. Neoplasm Staging. Nephrectomy

  • Genetic Alliance. consumer health - Transitional cell carcinoma.
  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19562529.001).
  • [ISSN] 1424-7860
  • [Journal-full-title] Swiss medical weekly
  • [ISO-abbreviation] Swiss Med Wkly
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Number-of-references] 41
  •  go-up   go-down


11. Kmetec A, Kaplan-Pavlovcic S, Ovcak Z: Transitional cell carcinoma involving the ureterovesical part of a transplanted ureter. Urol Int; 2003;71(1):122-3
MedlinePlus Health Information. consumer health - Kidney Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transitional cell carcinoma involving the ureterovesical part of a transplanted ureter.
  • Ureterovesical malignancy in the renal transplant recipient is an infrequent occurrence.
  • We report a woman with a cadaver kidney recipient, transplanted 10 years ago, with transitional-cell carcinoma at the ureterovesical part of the transplanted ureter invading the bladder muscle around the orifice.
  • Though aggressive surgery and chemotherapy of such patients is proposed, most patients die after an average of 16-17 months.
  • In our patient we have done partial ureter and bladder resection in order to preserve kidney graft and bladder.
  • We continued immunosuppressive treatment.
  • Our case suggests that nonaggressive operative treatment without chemotherapy in selected patients may provide comparable survival to patients with aggressive treatment, but with better quality of life.
  • [MeSH-major] Carcinoma, Transitional Cell / pathology. Kidney Transplantation / adverse effects. Ureter / transplantation. Ureteral Neoplasms / pathology. Urinary Bladder Neoplasms / pathology. Urologic Surgical Procedures / methods
  • [MeSH-minor] Female. Humans. Middle Aged. Neoplasm Invasiveness. Transplants / adverse effects. Urography

  • Genetic Alliance. consumer health - Transitional cell carcinoma.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 S. Karger AG, Basel
  • (PMID = 12845277.001).
  • [ISSN] 0042-1138
  • [Journal-full-title] Urologia internationalis
  • [ISO-abbreviation] Urol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


12. Helke C, May M, Hoschke B: [Gemcitabine and carboplatin chemotherapy in advanced transitional cell carcinoma in regard to patients with impaired renal function]. Aktuelle Urol; 2006 Sep;37(5):363-8
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Gemcitabine and carboplatin chemotherapy in advanced transitional cell carcinoma in regard to patients with impaired renal function].
  • [Transliterated title] Gemcitabine/Carboplatin-Chemotherapie in der Behandlung des metastasierten Urothelkarzinoms unter besonderer Berücksichtigung von Patienten mit eingeschränkter Nierenfunktion.
  • PURPOSE: The aim of this analysis is the evaluation of the activity and toxicity of gemcitabine and carboplatin in patients with advanced urothelial transitional carcinoma (TCC) with special regard to patients with impaired renal function.
  • In 15 patients (considered as renal unfit) a creatinine clearance of less than 60 mL/min (range: 31 - 59 mL/min) was seen.
  • RESULTS: Concerning the survival rate, no significant difference noticed between the two subgroups of renal impaired patients and patients with normal renal function was detected (median 13 vs. 14 months, p = 0.901).
  • Median time to progression was 5.34 months.
  • There was no restriction of renal function under chemotherapy in any single patient.
  • CONCLUSIONS: The chemotherapy combination of gemcitabine and carboplatin is definitely powerful for a first-line-therapy in patients with advanced TCC.
  • Decreases of effectiveness in cases of impaired renal function were not detected.
  • Patients with metastatic TCC should be entered onto well designed, randomised clinical trials with the gemcitabine/carboplatin combination to afford a tailored chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carboplatin / administration & dosage. Carcinoma, Transitional Cell / drug therapy. Deoxycytidine / analogs & derivatives. Kidney Failure, Chronic / complications. Kidney Function Tests. Ureteral Neoplasms / drug therapy. Urinary Bladder Neoplasms / drug therapy
  • [MeSH-minor] Aged. Aged, 80 and over. Disease Progression. Dose-Response Relationship, Drug. Female. Follow-Up Studies. Humans. Kidney Pelvis / pathology. Male. Middle Aged. Neoplasm Invasiveness / pathology. Neoplasm Metastasis / pathology. Prospective Studies. Survival Rate. Ureter / pathology. Urinary Bladder / pathology


13. Wu WJ, Ke HL, Yang YH, Li CC, Chou YH, Huang CH: Should patients with primary upper urinary tract cancer receive prophylactic intravesical chemotherapy after nephroureterectomy? J Urol; 2010 Jan;183(1):56-61
Hazardous Substances Data Bank. EPIRUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Should patients with primary upper urinary tract cancer receive prophylactic intravesical chemotherapy after nephroureterectomy?
  • PURPOSE: We assessed the efficacy of prophylactic intravesical chemotherapy for primary upper urinary tract urothelial cancer after nephroureterectomy during long-term followup.
  • We compared the bladder tumor recurrence rate, number of recurrence episodes, time to first bladder tumor recurrence, tumor type, percent of patients with cystectomy and percent who died of urothelial cancer, and the recurrence-free survival rate.
  • There were no significant differences in recurrence type, mean number of bladder tumor recurrences, percent of patients with cystectomy and the cancer specific survival rate.
  • Mean time to first bladder tumor recurrence was longer in groups 1 and 2.
  • CONCLUSIONS: Intravesical instillation of epirubicin or mitomycin C appears to be well tolerated and effective for preventing bladder recurrence and prolonging time to first bladder recurrence.
  • Patients should receive prophylactic intravesical chemotherapy after nephroureterectomy.
  • [MeSH-major] Antibiotics, Antineoplastic / administration & dosage. Carcinoma, Transitional Cell / prevention & control. Carcinoma, Transitional Cell / surgery. Epirubicin / administration & dosage. Kidney Neoplasms / prevention & control. Kidney Neoplasms / surgery. Mitomycin / administration & dosage. Neoplasm Recurrence, Local / prevention & control. Nephrectomy. Ureter / surgery. Ureteral Neoplasms / prevention & control. Ureteral Neoplasms / surgery
  • [MeSH-minor] Administration, Intravesical. Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Male. Middle Aged. Postoperative Care. Retrospective Studies. Time Factors. Young Adult


14. Troiano M, Corsa P, Raguso A, Cossa S, Piombino M, Guglielmi G, Parisi S: Radiation therapy in urinary cancer: state of the art and perspective. Radiol Med; 2009 Feb;114(1):70-82

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiation therapy in urinary cancer: state of the art and perspective.
  • Invasive urinary tumours are relatively rare, and their treatment may cause important changes in urinary, sexual and social functions.
  • A systematic review of external radiation therapy studies in urinary cancers was performed.
  • There are few controlled clinical trials using adjuvant or radical radiotherapy with or without chemotherapy in cancer of the kidney, ureter and urethra.
  • There are several reports on multimodality treatment in invasive bladder cancer: intravesical surgery and neoadjuvant chemotherapy to radiotherapy or concomitant radiochemotherapy with organ preservation.
  • The conclusions reached for renal cancer are controversial, and data on cancers of the urethra and ureter are few and inconclusive.
  • [MeSH-minor] Brachytherapy. Combined Modality Therapy. Controlled Clinical Trials as Topic. Cystectomy. Data Interpretation, Statistical. Dose Fractionation. Female. Humans. Kidney / pathology. Kidney Neoplasms / mortality. Kidney Neoplasms / pathology. Kidney Neoplasms / radiotherapy. Kidney Neoplasms / surgery. Male. Meta-Analysis as Topic. Neoplasm Staging. Nephrectomy. Organ Preservation. Prospective Studies. Radiotherapy Dosage. Radiotherapy, Adjuvant. Retrospective Studies. Survival Analysis. Time Factors. Ureter / pathology. Ureteral Neoplasms / drug therapy. Ureteral Neoplasms / mortality. Ureteral Neoplasms / pathology. Ureteral Neoplasms / radiotherapy. Urethra / pathology. Urethral Neoplasms / drug therapy. Urethral Neoplasms / mortality. Urethral Neoplasms / pathology. Urethral Neoplasms / radiotherapy. Urinary Bladder / pathology. Urinary Bladder Neoplasms / pathology. Urinary Bladder Neoplasms / radiotherapy. Urinary Bladder Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiother Oncol. 2000 Jul;56(1):29-35 [10869752.001]
  • [Cites] Oncologist. 2000;5(6):471-6 [11110598.001]
  • [Cites] Anticancer Res. 1998 May-Jun;18(3B):1931-4 [9677446.001]
  • [Cites] Am J Clin Oncol. 2003 Dec;26(6):558-62 [14663371.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Jan 1;40(1):121-7 [9422567.001]
  • [Cites] Cancer. 2004 Dec 1;101(11):2540-8 [15481058.001]
  • [Cites] Cancer. 1994 Nov 15;74(10):2819-27 [7954243.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Aug 30;33(1):173-8 [7642415.001]
  • [Cites] Radiother Oncol. 1997 May;43(2):155-7 [9192960.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1992;23(3):511-7 [1612951.001]
  • [Cites] J Urol. 1958 Feb;79(2):196-201 [13514867.001]
  • [Cites] J Urol. 2004 Oct;172(4 Pt 1):1271-5 [15371822.001]
  • [Cites] Radiother Oncol. 1992 May;24(1):41-4 [1620886.001]
  • [Cites] J Urol. 1982 Apr;127(4):671-4 [7069829.001]
  • [Cites] Strahlenther Onkol. 2005 Oct;181(10):632-7 [16220401.001]
  • [Cites] Semin Surg Oncol. 1997 May-Jun;13(3):208-14 [9143060.001]
  • [Cites] Radiother Oncol. 2005 Apr;75(1):34-43 [15878099.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 Feb 1;28(3):783 [8113125.001]
  • [Cites] J Clin Oncol. 2006 Dec 10;24(35):5536-44 [17158539.001]
  • [Cites] Cancer. 1993 Nov 15;72(10):3044-51 [8221572.001]
  • [Cites] Urology. 1977 Nov;10(5):414-7 [411207.001]
  • [Cites] Radiology. 1994 Dec;193(3):725-30 [7972814.001]
  • [Cites] J Clin Oncol. 2002 Jul 15;20(14):3061-71 [12118019.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Jan 15;37(2):259-67 [9069295.001]
  • [Cites] Urology. 2002 Jul;60(1):62-7; discussion 67-8 [12100923.001]
  • [Cites] Anticancer Res. 1997 Nov-Dec;17(6D):4771-80 [9494605.001]
  • [Cites] J Urol. 1996 Jun;155(6):1903-6 [8618283.001]
  • [Cites] Lancet. 2003 Jun 7;361(9373):1927-34 [12801735.001]
  • [Cites] Int J Cancer. 2000 Oct 20;90(5):287-94 [11091353.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1990 Sep;19(3):693-9 [2211217.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1993 Apr 2;25(5):783-90 [8478228.001]
  • [Cites] Cancer. 1970 Jan;25(1):26-40 [5410313.001]
  • [Cites] Tumori. 2006 May-Jun;92(3):202-6 [16869236.001]
  • [Cites] J Clin Oncol. 1996 Nov;14(11):2901-7 [8918486.001]
  • [Cites] Transplantation. 1986 Jan;41(1):63-6 [3510497.001]
  • [Cites] Semin Oncol. 1983 Dec;10(4):417-21 [6198728.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1992;24(3):463-8 [1399731.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Nov 1;57(3):665-72 [14529770.001]
  • [Cites] Neoplasma. 1998;45(6):380-3 [10210113.001]
  • [Cites] Radiother Oncol. 2005 Apr;75(1):44-7 [15878100.001]
  • [Cites] Strahlentherapie. 1985 Nov;161(11):673-7 [3907021.001]
  • [Cites] J Urol. 1998 Nov;160(5):1673-7 [9783929.001]
  • [Cites] J Urol. 1997 Mar;157(3):805-7; discussion 807-8 [9072571.001]
  • [Cites] Urology. 1995 Oct;46(4):499-504; discussion 504-5 [7571218.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 May 1;41(2):273-8 [9607341.001]
  • [Cites] J Surg Oncol. 1983 Aug;23(4):263-8 [6876802.001]
  • [Cites] J Clin Oncol. 2001 Feb 1;19(3):666-75 [11157016.001]
  • [Cites] J Urol. 1970 Jul;104(1):53-61 [5426710.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Jun 1;41(3):535-41 [9635699.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Mar 15;64(4):1168-73 [16376486.001]
  • [Cites] Clin Oncol (R Coll Radiol). 2006 Feb;18(1):52-9 [16477920.001]
  • [Cites] Acta Oncol. 2006;45(7):870-5 [16982552.001]
  • [Cites] Int Urol Nephrol. 1984;16(1):29-32 [6724827.001]
  • [Cites] Cancer. 1988 Jan 15;61(2):255-62 [3334959.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Jul 1;56(3):726-33 [12788178.001]
  • [Cites] Radiother Oncol. 2005 Oct;77(1):88-95 [15972239.001]
  • [Cites] J Clin Oncol. 1993 Nov;11(11):2150-7 [8229129.001]
  • [Cites] Br J Urol. 1982 Apr;54(2):136-51 [7044462.001]
  • [Cites] J Chin Med Assoc. 2005 Nov;68(11):522-30 [16323396.001]
  • [Cites] J Urol. 1991 Jan;145(1):45-50 [1984097.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 May 15;32(2):331-40 [7751174.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Dec 1;57(5):1310-6 [14630267.001]
  • [Cites] J Urol. 2001 Apr;165(4):1111-6 [11257649.001]
  • [Cites] Urology. 2004 Jan;63(1):73-7 [14751352.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1990 May;18(5):1131-7 [2347721.001]
  • [Cites] Radiother Oncol. 1999 Jul;52(1):1-14 [10577680.001]
  • [Cites] Lancet. 1999 Aug 14;354(9178):533-40 [10470696.001]
  • [Cites] J Clin Oncol. 1997 Mar;15(3):1022-9 [9060542.001]
  • [Cites] Tumori. 2002 Nov-Dec;88(6):500-2 [12597146.001]
  • [Cites] J Clin Oncol. 1998 Nov;16(11):3576-83 [9817278.001]
  • [Cites] Strahlentherapie Sonderb. 1981;76:169-75 [7303093.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 May 1;47(2):373-8 [10802362.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1987 May;13(5):665-72 [3553111.001]
  • [Cites] Br J Cancer. 2004 Jun 1;90(11):2106-11 [15150587.001]
  • [Cites] J Clin Oncol. 1996 Jan;14(1):119-26 [8558186.001]
  • [Cites] Br J Urol. 1997 Jul;80(1):44-9 [9240179.001]
  • [Cites] Scand J Urol Nephrol. 1977;11(3):277-81 [594674.001]
  • (PMID = 19082788.001).
  • [ISSN] 0033-8362
  • [Journal-full-title] La Radiologia medica
  • [ISO-abbreviation] Radiol Med
  • [Language] eng; ita
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 80
  •  go-up   go-down


15. Raman JD, Ng CK, Scherr DS, Margulis V, Lotan Y, Bensalah K, Patard JJ, Kikuchi E, Montorsi F, Zigeuner R, Weizer A, Bolenz C, Koppie TM, Isbarn H, Jeldres C, Kabbani W, Remzi M, Waldert M, Wood CG, Roscigno M, Oya M, Langner C, Wolf JS, Ströbel P, Fernández M, Karakiewcz P, Shariat SF: Impact of tumor location on prognosis for patients with upper tract urothelial carcinoma managed by radical nephroureterectomy. Eur Urol; 2010 Jun;57(6):1072-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of tumor location on prognosis for patients with upper tract urothelial carcinoma managed by radical nephroureterectomy.
  • BACKGROUND: There is a lack of consensus regarding the prognostic significance of ureteral versus renal pelvic upper tract urothelial carcinoma (UTUC).
  • OBJECTIVE: To investigate the association of tumor location on outcomes for UTUC in an international cohort of patients managed by radical nephroureterectomy (RNU).
  • MEASUREMENTS: Data accrued included age, gender, race, surgical approach (open vs laparoscopic), tumor pathology (stage, grade, lymph node status), tumor location, use of perioperative chemotherapy, prior endoscopic therapy, urothelial carcinoma recurrence, and mortality from urothelial carcinoma.
  • Tumor location was divided into two groups (renal pelvis and ureter) based on the location of the dominant tumor.
  • On multivariate analysis, only pathologic tumor (pT) classification (p<0.001), grade (p<0.02), and lymph node status (p<0.001) were associated with disease recurrence and cancer-specific survival.
  • When adjusting for these variables, there was no difference in the probability of disease recurrence (hazard ratio [HR]: 1.22; p=0.133) or cancer death (HR: 1.23; p=0.25) between ureteral and renal pelvic tumors.
  • Adding tumor location to a base prognostic model for disease recurrence and cancer death that included pT stage, tumor grade, and lymph node status only improved the predictive accuracy of this model by 0.1%.
  • CONCLUSIONS: There is no difference in outcomes between patients with renal pelvic tumors and with ureteral tumors following nephroureterectomy.
  • These data support the current TNM staging system, whereby renal pelvic and ureteral carcinomas are classified as one integral group of tumors.
  • [MeSH-major] Carcinoma / pathology. Kidney Neoplasms / pathology. Kidney Pelvis / pathology. Ureter / pathology. Urethral Neoplasms / pathology. Urothelium / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Multicenter Studies as Topic. Neoplasm Staging. Nephrectomy. Prognosis. Proportional Hazards Models. Recurrence. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2009 European Association of Urology. Published by Elsevier B.V. All rights reserved.
  • (PMID = 19619934.001).
  • [ISSN] 1873-7560
  • [Journal-full-title] European urology
  • [ISO-abbreviation] Eur. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


16. Kim DS, Lee YH, Cho KS, Cho NH, Chung BH, Hong SJ: Lymphovascular invasion and pT stage are prognostic factors in patients treated with radical nephroureterectomy for localized upper urinary tract transitional cell carcinoma. Urology; 2010 Feb;75(2):328-32
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • LVI was related to higher pT stage, high tumor grade, sessile architecture, and squamous differentiation.
  • On univariate analysis, tumor architecture, squamous differentiation, LVI, tumor grade, and pT stage influenced disease-specific survival.
  • LVI and pT stage would be helpful for selecting patients who are appropriate for postoperative adjuvant chemotherapy.
  • [MeSH-major] Carcinoma, Transitional Cell / pathology. Carcinoma, Transitional Cell / surgery. Kidney Neoplasms / pathology. Kidney Neoplasms / surgery. Kidney Pelvis. Nephrectomy. Ureter / surgery. Ureteral Neoplasms / pathology. Ureteral Neoplasms / surgery. Vascular Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Prognosis. Survival Rate

  • Genetic Alliance. consumer health - Transitional cell carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Elsevier Inc. All rights reserved.
  • [CommentIn] Urology. 2010 Feb;75(2):332-3 [20152482.001]
  • [CommentIn] Urology. 2010 Feb;75(2):333 [20152483.001]
  • (PMID = 20018349.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Zhang Y, Gu ZY, Tian Z, Yang C, Cai XY: Oral metastasis from primary transitional cell carcinoma of the renal pelvis: report of a case. Int J Oral Maxillofac Surg; 2010 Jul;39(7):737-9
MedlinePlus Health Information. consumer health - Oral Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oral metastasis from primary transitional cell carcinoma of the renal pelvis: report of a case.
  • Transitional cell carcinoma of the renal pelvis is initially a slow growing tumor arising from the transitional epithelium of the mucous membrane of the renal pelvis.
  • The authors report an unusual case of transitional cell carcinoma of the renal pelvis metastasized to the oral cavity and lung simultaneously in a 74-year-old man, which occurred 1 year after a left nephroureterectomy.
  • The patient underwent six courses of chemotherapy (gemcitabine, oxaliplatin, fluorouracil and nedaplatin), and received radiotherapy for the oral lesion.
  • The symptoms were alleviated, but the tumor recurred in the oral cavity 2 years later.
  • [MeSH-major] Carcinoma, Transitional Cell / secondary. Kidney Neoplasms / pathology. Kidney Pelvis / pathology. Mouth Neoplasms / secondary
  • [MeSH-minor] Aged. Chemotherapy, Adjuvant. Fatal Outcome. Follow-Up Studies. Humans. Lung Neoplasms / secondary. Male. Neoadjuvant Therapy. Neoplasm Recurrence, Local / pathology. Nephrectomy. Radiotherapy, Adjuvant. Ureter / surgery

  • Genetic Alliance. consumer health - Transitional cell carcinoma.
  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 International Association of Oral and Maxillofacial Surgeons. Published by Elsevier Ltd. All rights reserved.
  • (PMID = 20236801.001).
  • [ISSN] 1399-0020
  • [Journal-full-title] International journal of oral and maxillofacial surgery
  • [ISO-abbreviation] Int J Oral Maxillofac Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  •  go-up   go-down


18. Corgna E, Betti M, Gatta G, Roila F, De Mulder PH: Renal cancer. Crit Rev Oncol Hematol; 2007 Dec;64(3):247-62
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Renal cancer.
  • In Europe, renal cancer (that is neoplasia of the kidney, renal pelvis or ureter (ICD-9 189 and ICD-10 C64-C66)) ranks as the seventh most common malignancy in men amongst whom there are 29,600 new cases each year (3.5% of all cancers).
  • A familial history of renal carcinoma is also likely to increase the risk.
  • Renal carcinoma may remain clinically occult for most of its course.
  • Approximately 30% of patients with renal carcinoma present with metastatic disease, 25% with locally advanced renal carcinoma and 45% with localized disease.
  • Metastases are typically found in the lung, soft tissue, bone, liver, cutaneous sites, and central nervous system.
  • The most important staging technique is a computed tomography (CT) scan of the whole abdomen.
  • Survival rates are more favourable for patients with tumours confined to the kidney.
  • Five-year survival for patients with metastatic renal carcinoma is comprised between 0 and 20%.
  • Radical nephrectomy is the standard intervention for renal cancer.
  • Intrinsic resistance to chemotherapy has long been a hallmark of renal carcinoma.
  • Limited options are available for the systemic therapy, and no chemotherapeutic regimen is accepted as a standard of care.
  • Biologic agents represent the major effective therapies for widespread metastatic renal cancer.
  • [MeSH-major] Kidney Neoplasms / diagnosis. Kidney Neoplasms / pathology. Kidney Neoplasms / therapy
  • [MeSH-minor] Humans. Neoplasm Staging. Prevalence. Prognosis

  • Genetic Alliance. consumer health - Kidney cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17662611.001).
  • [ISSN] 1040-8428
  • [Journal-full-title] Critical reviews in oncology/hematology
  • [ISO-abbreviation] Crit. Rev. Oncol. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Ireland
  • [Number-of-references] 134
  •  go-up   go-down


19. Gallagher DJ, Milowsky MI, Ishill N, Trout A, Boyle MG, Riches J, Fleisher M, Bajorin DF: Detection of circulating tumor cells in patients with urothelial cancer. Ann Oncol; 2009 Feb;20(2):305-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of circulating tumor cells in patients with urothelial cancer.
  • BACKGROUND: Approximately 50% of patients with metastatic urothelial cancer (UC) respond to chemotherapy and several months of therapy is required to assess for radiographic response.
  • Blood-based biomarkers may identify patients in whom a specific therapy provides clinical benefit, and this study sought to characterize circulating tumor cells (CTCs) in patients with metastatic UC.
  • One-third of patients have five or more CTCs providing a potential early marker to monitor response to chemotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18836088.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


20. Thalmann GN, Markwalder R, Walter B, Studer UE: Long-term experience with bacillus Calmette-Guerin therapy of upper urinary tract transitional cell carcinoma in patients not eligible for surgery. J Urol; 2002 Oct;168(4 Pt 1):1381-5
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term experience with bacillus Calmette-Guerin therapy of upper urinary tract transitional cell carcinoma in patients not eligible for surgery.
  • PURPOSE: Carcinoma in situ and urothelial tumors of the upper urinary tract become problematic in cases of bilateral occurrence or solitary kidney.
  • Perfusions with bacillus Calmette-Guerin (BCG) have been reported beneficial, however, only long-term results will determine the validity of this treatment.
  • MATERIALS AND METHODS: We retrospectively evaluated the results of BCG therapy for upper urinary tract disease in 37 patients.
  • All 37 patients had undergone previous surgical treatment for urothelial cancer, had a positive cytology or biopsy for upper urinary tract cancer and were ineligible for radical nephroureterectomy with a bladder cuff.
  • After placement of a 10Fr nephrostomy tube with the patient under local anesthesia 6 weekly perfusions of BCG were administered after radiological documentation of unhindered flow from the renal pelvis to the bladder or urinary diversion.
  • A total of 25 renal units were treated with curative intent for carcinoma in situ and 16 renal units were treated for Ta or higher urothelial tumors in an adjuvant setting after endoscopic resection.
  • RESULTS: In 37 patients 41 renal units were treated with BCG perfusions and were followed for a median of 42 months (range 8 to 137).
  • In 1 patient BCG inflammation and in 2 others severe septicemia developed after the first perfusion.
  • There was no tumor seeding along the nephrostomy tract in any patient.
  • BCG perfusion therapy did not alter renal function.
  • CONCLUSIONS: BCG perfusion therapy of the upper urinary tract for papillary tumors or carcinoma in situ is a valid treatment option with acceptable side effects for patients not amenable to conventional radical surgical therapy.
  • BCG therapy of upper urinary tract urothelial tumors may prevent patients from requiring dialysis and provides cure in those with carcinoma in situ of the upper urinary tract.
  • In this negatively selected patient population BCG buys time for some but does not provide cure except for carcinoma in situ.
  • [MeSH-major] BCG Vaccine / therapeutic use. Carcinoma in Situ / drug therapy. Carcinoma, Transitional Cell / drug therapy. Kidney Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / surgery. Neoplasm Staging. Nephrectomy. Nephrostomy, Percutaneous. Perfusion. Retrospective Studies. Survival Rate. Ureter / pathology. Ureter / surgery. Ureteral Neoplasms / drug therapy. Ureteral Neoplasms / mortality. Ureteral Neoplasms / pathology. Ureteral Neoplasms / surgery. Urinary Bladder Neoplasms / drug therapy. Urinary Bladder Neoplasms / mortality. Urinary Bladder Neoplasms / pathology. Urinary Bladder Neoplasms / surgery. Urinary Diversion

  • Genetic Alliance. consumer health - Transitional cell carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12352398.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BCG Vaccine
  •  go-up   go-down


21. Varan A, Akyuz C, Sari N, Buyukpamukçu N, Cağlar M, Buyukpamukçu M: Renal cell carcinoma in children: experience of a single center. Nephron Clin Pract; 2007;105(2):c58-61
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Renal cell carcinoma in children: experience of a single center.
  • OBJECTIVE: To evaluate the clinical features and outcome of children with renal cell carcinoma (RCC).
  • Clinical features, histopathology, treatment regimens and outcomes of the patients were evaluated.
  • CONCLUSION: Nephroureterectomy is the main treatment modality, and it is sufficient for stage I patients.
  • For patients with stage II-IV RCC, interferon-alpha and/or actinomycin D-based chemotherapy is the treatment of choice.
  • [MeSH-major] Carcinoma, Renal Cell / pathology. Carcinoma, Renal Cell / therapy. Kidney Neoplasms / pathology. Kidney Neoplasms / therapy
  • [MeSH-minor] Adolescent. Antibiotics, Antineoplastic / therapeutic use. Antimetabolites, Antineoplastic / therapeutic use. Antineoplastic Agents / therapeutic use. Child. Child, Preschool. Cisplatin / therapeutic use. Dactinomycin / therapeutic use. Female. Fluorouracil / therapeutic use. Follow-Up Studies. Humans. Male. Neoplasm Staging. Nephrectomy. Retrospective Studies. Survival Analysis. Treatment Outcome. Ureter / surgery

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DACTINOMYCIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2007 S. Karger AG, Basel.
  • (PMID = 17135769.001).
  • [ISSN] 1660-2110
  • [Journal-full-title] Nephron. Clinical practice
  • [ISO-abbreviation] Nephron Clin Pract
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 1CC1JFE158 / Dactinomycin; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


22. Miao M, Kong CZ, Li ZH, Liu XK, Sun ZX: [The clinical study for reducing bladder cancer recurrence after surgical treatment for renal pelvic carcinoma]. Zhonghua Wai Ke Za Zhi; 2009 May 15;47(10):728-30
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The clinical study for reducing bladder cancer recurrence after surgical treatment for renal pelvic carcinoma].
  • OBJECTIVE: To investigate the clinical methods for reducing bladder cancer recurrence after surgical treatment for renal pelvic carcinoma.
  • METHODS: From October 1997 to December 2007, the data of 227 patients undergoing total nephroureterectomy for clinically localized transitional cell carcinoma of the renal pelvis with follow-up results were analyzed retrospectively, including 126 cases of male and 101 cases of female, and the age was 34 to 78 years old.
  • There were 2 kinds of technique used in the dissection of bladder wall circumferentially around the ureteral orifice.
  • Technique A was dissection along the ipsilateral ureter to the bladder wall.
  • Technique B was dissection along the vas deferens to the bladder wall circumferentially around the ipsilateral ureteral orifice and division of the lateral vesical ligament to reach the seminal vesicle.
  • Prophylactic intravesical chemotherapy included 3 method.
  • Method 1 was intraoperative intravesical chemotherapy and then administrated once a week, 10 times in total.
  • Method 2 was intraoperative intravesical chemotherapy and then administrated once a week from the 4(th) week after operation, 10 times in total.
  • Method 3 was intravesical chemotherapy was given once a week from the 4(th) week after operation, 10 times in total.
  • The time of follow-up was 1 to 10 years with regular cystoscopy.
  • The postoperative recurrence rates of bladder cancer in patients using 3 kinds of intravesical chemotherapy regimen were 17.9% (11/67), 20.8% (10/48) and 33.3% (17/51), respectively.
  • There was significant difference between the recurrence rates of patients using method 1 and method 3 intravesical chemotherapy (P < 0.05).
  • CONCLUSION: Complete removal of the bladder mucosa circumferentially around the ureteral orifice, administration of the intraoperative intravesical chemotherapy instillation and instillation once a week may be a useful approach to reduce the recurrence of bladder cancer after operation for renal pelvic carcinoma.
  • [MeSH-major] Carcinoma, Renal Cell / surgery. Kidney Neoplasms / surgery. Kidney Pelvis. Urinary Bladder Neoplasms / secondary
  • [MeSH-minor] Adult. Aged. Chemotherapy, Cancer, Regional Perfusion. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / prevention & control. Postoperative Care. Retrospective Studies

  • Genetic Alliance. consumer health - Kidney cancer.
  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19615202.001).
  • [ISSN] 0529-5815
  • [Journal-full-title] Zhonghua wai ke za zhi [Chinese journal of surgery]
  • [ISO-abbreviation] Zhonghua Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


23. Reubi JC: In vitro evaluation of VIP/PACAP receptors in healthy and diseased human tissues. Clinical implications. Ann N Y Acad Sci; 2000;921:1-25
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In vitro evaluation of VIP/PACAP receptors in healthy and diseased human tissues. Clinical implications.
  • The evaluation of peptide receptors in man is relevant to identifying the physiological target tissues of a given peptide and to selecting diseases with a sufficient receptor overexpression for diagnostic or therapeutic intervention.
  • VIP/PACAP receptors have been evaluated in normal and diseased human non-neuronal tissues by using in vitro receptor autoradiography with 125I-VIP or 125I-PACAP in tissue sections.
  • As assessed by subtype-selective VIP analogs, VIP receptors of the VPAC1 subtype are found in a wide variety of tissues including liver, breast, kidney, prostate, ureter, bladder, pancreatic ducts, gastrointestinal mucosa, lung, thyroid, adipose, and lymphoid tissues.
  • VIP/PACAP receptors are expressed in the majority of the most frequently occurring human tumors, including breast, prostate, pancreas, lung, colon, stomach, liver, and bladder carcinomas, as well as lymphomas and meningiomas, predominantly as VPAC1 receptors, as do their tissues of origin.
  • Moreover, the receptor expression in tumors is the molecular basis for clinical applications of VIP/PACAP such as in vivo scintigraphy and radiotherapy of tumors as well as VIP/PACAP analog treatment for tumor growth inhibition.
  • [MeSH-minor] Autoradiography. Epithelium / metabolism. Female. Humans. In Vitro Techniques. Male. Neoplasm Metastasis. Neoplasms / drug therapy. Neoplasms / metabolism. Neoplasms / radiotherapy. Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide. Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide, Type I. Receptors, Vasoactive Intestinal Peptide, Type II. Receptors, Vasoactive Intestinal Polypeptide, Type I. Tissue Distribution


24. Goel MC, Mahendra V, Roberts JG: Percutaneous management of renal pelvic urothelial tumors: long-term followup. J Urol; 2003 Mar;169(3):925-9; discussion 929-30
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Percutaneous management of renal pelvic urothelial tumors: long-term followup.
  • PURPOSE: We present the long-term outcome of percutaneous resection of renal urothelial tumor.
  • MATERIALS AND METHODS: A total of 24 patients underwent primary percutaneous resection of renal urothelial tumor.
  • Patients with multi-segmental pelvicaliceal system involvement, stage greater than pT1, high grade histology or additional ureteral tumors were considered for nephroureterectomy.
  • Topical chemotherapy (mitomycin C or epirubicin) was administered via nephrostomy tube or intravesical instillation after Double-J stent (Medical Engineering Corp., New York, New York) insertion.
  • RESULTS: Of the 24 cases 2 had squamous cell carcinoma, 5 had grade III transitional cell carcinoma, 15 had grade I to II transitional cell carcinoma and 2 had no tumor.
  • All patients with high grade disease died of malignancy except one (with no further treatment) and 6 of the 15 patients with low grade noninvasive transitional cell carcinoma underwent nephroureterectomy during followup either due to progression of disease, concomitant tumor or complications.
  • Two patients with solitary kidneys died of renal failure unrelated to malignancy.
  • All excised tracks from patients who underwent nephroureterectomy and the renal fossae were free of tumor on histopathological examination.
  • CONCLUSIONS: Percutaneous resection of transitional cell tumor should be considered primarily in patients with early stage disease excluding tumors crossing caliceal infundibula, ureteropelvic junction tumor, tumor extending over multiple calices and synchronous ureteral tumors.
  • [MeSH-major] Carcinoma, Transitional Cell / therapy. Kidney Neoplasms / therapy
  • [MeSH-minor] Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / therapy. Endoscopy. Female. Follow-Up Studies. Humans. Kidney Pelvis. Male. Middle Aged. Neoplasm Recurrence, Local. Nephrectomy. Ureter / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Urol. 2003 Mar;169(3):936-7 [12576816.001]
  • (PMID = 12576814.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Washino S, Terauchi F, Matsuzaki A, Kobayashi Y: [Two cases of squamous cell carcinoma of upper urinary tract with hypercalcemia]. Nihon Hinyokika Gakkai Zasshi; 2008 Sep;99(6):703-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Case 1; a 54 year old female with primary squamous cell carcinoma (SCC) of right ureter showed marked hypercalcemia and leukocytosis.
  • Although chemotherapy of cisplatin and 5-fluorouracil with radiotherapy was effective, thereafter recurrence was occurred in renal pelvis, and the patient died 17 months after the initiation of therapy.
  • Case 2; a 54 year old male of primary SCC of right renal pelvis with local lymphadenopathy and anterior mediastinal metastases showed marked hypercalcemia.
  • Although the patient was administered UFT with palliative radiotherapy to the anterior mediastinum, he died 2 months after the initiation of therapy.
  • [MeSH-major] Carcinoma, Squamous Cell / complications. Hypercalcemia / etiology. Kidney Neoplasms / complications. Kidney Pelvis. Ureteral Neoplasms / complications
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / administration & dosage. Combined Modality Therapy. Fatal Outcome. Female. Fluorouracil / administration & dosage. Granulocyte Colony-Stimulating Factor / biosynthesis. Granulocyte Colony-Stimulating Factor / blood. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Parathyroid Hormone-Related Protein / biosynthesis. Parathyroid Hormone-Related Protein / blood. Radiotherapy. Tegafur / administration & dosage. Uracil / administration & dosage

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18939454.001).
  • [ISSN] 0021-5287
  • [Journal-full-title] Nihon Hinyōkika Gakkai zasshi. The japanese journal of urology
  • [ISO-abbreviation] Nippon Hinyokika Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Parathyroid Hormone-Related Protein; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 1548R74NSZ / Tegafur; 56HH86ZVCT / Uracil; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil; 1-UFT protocol
  •  go-up   go-down


26. Brown GA, Busby JE, Wood CG, Pisters LL, Dinney CP, Swanson DA, Grossman HB, Pettaway CA, Munsell MF, Kamat AM, Matin SF: Nephroureterectomy for treating upper urinary tract transitional cell carcinoma: Time to change the treatment paradigm? BJU Int; 2006 Dec;98(6):1176-80
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nephroureterectomy for treating upper urinary tract transitional cell carcinoma: Time to change the treatment paradigm?
  • PATIENTS AND METHODS: The records of patients who had a nephroureterectomy for UUT-TCC at our institution from 1986 to 2004 were reviewed for clinical, pathological and treatment period data.
  • The evaluation of treatment outcome during three periods of the study showed no significant effect on DSS.
  • Patients with high-stage and high-grade disease continue to fare poorly, suggesting a need for changing the treatment protocol.
  • Judiciously applying a multimodal approach to the management of high-risk patients by incorporating neoadjuvant chemotherapy and surgical resection might provide, for the first time, the opportunity to improve patient outcome.
  • [MeSH-major] Carcinoma, Transitional Cell / surgery. Kidney Neoplasms / surgery. Nephrectomy / methods. Ureteral Neoplasms / surgery
  • [MeSH-minor] Aged. Cohort Studies. Disease-Free Survival. Female. Follow-Up Studies. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoadjuvant Therapy / methods. Neoplasm Recurrence, Local / surgery. Neoplasm Staging / methods. Prognosis. Treatment Outcome. Ureter / surgery

  • Genetic Alliance. consumer health - Transitional cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Eur Urol. 2007 Apr;51(4):1141-2 [17415912.001]
  • (PMID = 17125474.001).
  • [ISSN] 1464-4096
  • [Journal-full-title] BJU international
  • [ISO-abbreviation] BJU Int.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA91846; United States / NCI NIH HHS / CA / T32 CA079449-06
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


27. Cho KS, Cho NH, Park SY, Cho SY, Choi YD, Chung BH, Yang SC, Hong SJ: Prognostic impact of peripelvic fat invasion in pT3 renal pelvic transitional cell carcinoma. J Korean Med Sci; 2008 Jun;23(3):434-8
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic impact of peripelvic fat invasion in pT3 renal pelvic transitional cell carcinoma.
  • Renal pelvic transitional cell carcinoma (TCC), which invades beyond muscularis into peripelvic fat or the renal parenchyma, is diagnosed as stage pT3 despite its structural complexity.
  • We evaluated the prognostic impact of peripelvic fat invasion in pT3 renal pelvic TCC.
  • Between 1986 and 2004, the medical records on 128 patients who were surgically treated for renal pelvic TCC were retrospectively reviewed.
  • On univariate analysis, sex, age, concomitant bladder tumors, concomitant ureter tumors, lymphadenectomy, adjuvant chemotherapy, tumor grade, multiplicity, renal parenchymal invasion, and carcinoma in situ did not influence the disease-specific survival (p>0.05).
  • In conclusion, peripelvic fat invasion is a strong prognostic factor in pT3 renal pelvic TCC.
  • Thus, systemic adjuvant therapy should be considered in the presence of peripelvic fat invasion, even if the lymph nodes are not involved.
  • [MeSH-major] Adipose Tissue / pathology. Carcinoma, Transitional Cell / pathology. Kidney Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Follow-Up Studies. Humans. Lymph Nodes / pathology. Male. Middle Aged. Neoplasm Invasiveness. Pelvis. Prognosis. Retrospective Studies. Survival Analysis

  • Genetic Alliance. consumer health - Transitional cell carcinoma.
  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2002 Jun 15;94(12):3150-6 [12115347.001]
  • [Cites] J Urol. 1946 Apr;55:366-72 [21020382.001]
  • [Cites] JAMA. 1971 Nov 8;218(6):845-54 [4939530.001]
  • [Cites] J Urol. 1978 May;119(5):594-7 [660726.001]
  • [Cites] J Urol. 1980 May;123(5):629-31 [7420546.001]
  • [Cites] Cancer. 1988 Nov 1;62(9):2016-20 [3167813.001]
  • [Cites] Cancer. 1990 Nov 1;66(9):1919-23 [2224787.001]
  • [Cites] J Urol. 1991 Jun;145(6):1159-63 [2033684.001]
  • [Cites] Cancer. 1992 Apr 1;69(7):1773-5 [1551062.001]
  • [Cites] Urology. 1995 Dec;46(6):796-800 [7502418.001]
  • [Cites] CA Cancer J Clin. 1998 Jan-Feb;48(1):6-29 [9449931.001]
  • [Cites] Urology. 1998 Oct;52(4):594-601 [9763077.001]
  • [Cites] Am J Surg Pathol. 1998 Dec;22(12):1435-48 [9850170.001]
  • [Cites] Eur J Cancer. 1999 May;35(5):738-43 [10505034.001]
  • [Cites] Am J Surg Pathol. 2004 Dec;28(12):1545-52 [15577672.001]
  • [Cites] J Urol. 2005 Dec;174(6):2120-3; discussion 2124 [16280740.001]
  • [Cites] J Urol. 2004 Feb;171(2 Pt 1):621-5 [14713773.001]
  • (PMID = 18583879.001).
  • [ISSN] 1011-8934
  • [Journal-full-title] Journal of Korean medical science
  • [ISO-abbreviation] J. Korean Med. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2526530
  •  go-up   go-down


28. Mouracade P: Re: Should patients with primary upper urinary tract cancer receive prophylactic intravesical chemotherapy after nephroureterectomy?: W. J. Wu, H. L. Ke, Y. H. Yang, C. C. Li, Y. H. Chou and C. H. Huang J Urol 2010; 183: 56-61. J Urol; 2010 Oct;184(4):1571
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Re: Should patients with primary upper urinary tract cancer receive prophylactic intravesical chemotherapy after nephroureterectomy?: W. J. Wu, H. L. Ke, Y. H. Yang, C. C. Li, Y. H. Chou and C. H. Huang J Urol 2010; 183: 56-61.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Kidney Neoplasms / prevention & control. Neoplasm Recurrence, Local / prevention & control. Neoplasms, Second Primary / prevention & control. Nephrectomy. Ureter / surgery. Ureteral Neoplasms / prevention & control. Urinary Bladder Neoplasms / prevention & control

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] J Urol. 2010 Jan;183(1):56-61 [19913833.001]
  • (PMID = 20728904.001).
  • [ISSN] 1527-3792
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down






Advertisement